Summit Therapeutics to Present at JMP Securities Life Sciences Conference

OXFORD, United Kingdom, June 16, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ: SMMT) (AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference, 21 June 2016 at 9:30am EDT in New York City.

A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.

About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

-END-

You May Also Be Interested In

• H.B. Fuller Confirms Receipt of Unsolicited Proposal for Building Adhesive Solutions Segment
• Bolt Metals to Rebrand as 26 Metals Inc. and Adopt the Ticker "IRON," Highlighting Its Focus on Flagship Florália Iron Project in Brazil's Iron Quadrangle
• Miller Barondess Files Lawsuit Alleging Attorney and Law Firms Enabled One of California's Largest Real Estate Ponzi Schemes